NRX Pharma Wins $11.2M DARPA Contract For Depression Trial
NRX Pharmaceuticals' subsidiary, NRx Defense Systems, has secured a prime contract with DARPA valued at approximately $11.2 million to conduct the SPARC-TMS clinical trial for treatment-resistant depression. Initially, about $6.7 million is obligated, payable upon milestone achievement.
NRX Pharmaceuticals, through its subsidiary NRx Defense Systems, has entered into a prime contract with DARPA to conduct the SPARC-TMS clinical trial in treatment-resistant depression. 7 million initially obligated, and payment is tied to milestone achievement.